title: Highlights from the FDA antiviral drug advisory committee meetings, February 27-March 1, 1996.
authors.forename: R
authors.initials: R
authors.lastname: Baker
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage*; D018795:Device Approval; D017277:Drug Approval; D004359:Drug Therapy, Combination; D013006:Growth Hormone / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D019382:Human Growth Hormone; D006801:Humans; D019469:Indinavir; D011725:Pyridines / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use*; D019438:Ritonavir; D013844:Thiazoles / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration; D014633:Valine / Q000627:therapeutic use; D014773:Virology / Q000295:instrumentation / Q000379:methods
chemical_list: D000998:Antiviral Agents; D017320:HIV Protease Inhibitors; D011725:Pyridines; D011994:Recombinant Proteins; D013844:Thiazoles; D019382:Human Growth Hormone; D019469:Indinavir; D013006:Growth Hormone; D014633:Valine; D019438:Ritonavir